The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis

Trial Profile

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2015

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 08 Oct 2015 Results published in the Thrombosis and Haemostasis
    • 11 Jun 2014 Status changed from active, no longer recruiting to completed; according to ClinicalTrials.gov record.
    • 23 May 2014 Planned End Date changed from 1 Apr 2014 to 1 May 2014; according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top